These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 27019997)

  • 21. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
    Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
    Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
    Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
    Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on immune checkpoint inhibitors in lung cancer.
    Creelan BC
    Cancer Control; 2014 Jan; 21(1):80-9. PubMed ID: 24357746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
    Chow LQ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
    Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
    Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy.
    Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Abolghasemi H; Ghaffari SH; Momeny M; Bashash D
    Eur J Pharmacol; 2021 Oct; 909():174404. PubMed ID: 34363829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
    Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
    Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for Advanced Lung Cancer.
    Asmar R; Rizvi NA
    Cancer J; 2015; 21(5):383-91. PubMed ID: 26389763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
    Okuyama R
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
    Champiat S; Ileana E; Giaccone G; Besse B; Mountzios G; Eggermont A; Soria JC
    J Thorac Oncol; 2014 Feb; 9(2):144-53. PubMed ID: 24419410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
    Zielinski C; Knapp S; Mascaux C; Hirsch F
    Ann Oncol; 2013 May; 24(5):1170-9. PubMed ID: 23393121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immune checkpoint inhibitors in lung cancer].
    Koleczko S; Wolf J
    Internist (Berl); 2020 Jul; 61(7):676-681. PubMed ID: 32462250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
    Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
    Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the immune system to treat lung cancer: rationale and clinical experience.
    Guibert N; Delaunay M; Mazières J
    Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.